Sandeep Mahindra
Head of Investor Relations
Replay available
Infosys Limited American Depositary Shares (NYSE: INFY) Q3 2026 earnings conference call, held 2026-01-14. Replay captured from the company's public earnings webcast.

Head of Investor Relations
Chief Executive Officer & Managing Director
Chief Financial Officer
Analyst, JP Morgan
Analyst, TD Cowen
Analyst, Ambit Capital
Analyst, Motilal Oswal
Analyst, Guggenheim Securities
Analyst, Nuama
Analyst, BMO Capital Markets
Analyst, Equitous Securities
Analyst, Susquehanna International
Good day and welcome to Infosys Limited Q3 FI26 earnings conference call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star then zero on your touch-tone phone. Please note that this conference is being recorded. And I'll hand the conference over to Mr. Sandeep Mahindra Thank you, and over to you, Mr. Mahindra. Hello, everyone, and welcome to Infosys' earnings call for Q3 FY26. Let me start by wishing all of you a very happy new year. Joining us on this call is CEO and MD, Mr. Falil Parekh, CFO, Mr. Jayesh Sangrajka, along with other members of the leadership team. We'll start the call with some remarks on the performance of the company, subsequent to which the call will be opened up for questions. Please note that anything we say that refers to our future outlook is a forward-looking statement that must be read in conjunction with the risks that the company faces. A complete statement and explanation of these risks is available in our filings with the SEC, which can be found on www.sec.gov. I'd now like to pass on the call to Salil. Thanks, Sandeep. Good evening and good morning to everyone on the call. Thank you for joining us. Warm wishes to you for the new year. We had a strong performance in Q3. Our revenues grew 0.6% sequentially and 1.7% year on year in constant currency terms. Our large deals were at $4.8 billion with 57% net new. This was across 26 deals. Our adjusted operating margin was 21.2%. We generated free cash flow of $915 million. One of the most significant large deals we won was with the National Health Service in the UK. This $1.6 billion de...